Literature DB >> 8385857

Prognostic factors related to recurrent endometrial carcinoma following initial surgery.

N Vavra1, U Denison, H Kucera, M Barrada, C Kurz, H Salzer, P Sevelda.   

Abstract

Site of recurrence and histological type are significant prognostic factors for survival in recurrent endometrial carcinoma. The aim of this retrospective analysis of 56 patients suffering from recurrences of endometrial carcinoma following initial surgery was to establish the prognostic relevance that the following factors had on the survival rate: age, primary tumor stage, histological assessment (papillary vs non-papillary), postoperative adjuvant radiation therapy, recurrence free interval (< 24 months, > 24 months) and localisation of recurrence. The univariate analysis showed a significantly longer median survival time after recurrence for the following parameters: local recurrence vs extra vaginal recurrence (77.5 months vs 15.7 months, p = 0.02), non-papillary vs papillary carcinoma (36.1 months vs 7.7 months, p = 0.02), no adjuvant irradiation vs adjuvant irradiation (82.0 months vs 8.8 months, p = 0.007). Patients after adjuvant radiation treatment and patients suffering from papillary carcinomas have a significantly higher proportion of patients with distant metastasis (patients with adjuvant radiation treatment: Chi-square test: p = 0.001; patients suffering from papillary carcinomas: p = 0.033). In the case of local recurrences, a three year survival rate of 54% can be achieved with radiation treatment. Recurrences of papillary endometrial carcinomas and patients suffering from distant metastasis on the other hand, show very low survival rates if they are treated with radiation therapy (papillary carcinomas: three-year survival rate of 18%, patients suffering from distant metastasis: 19%). These patients should be included in randomised studies with a view to examining the therapeutic effects of either additional or exclusive treatment with chemotherapy.

Entities:  

Mesh:

Year:  1993        PMID: 8385857     DOI: 10.3109/00016349309013373

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

1.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer.

Authors:  O O Agboola; E Grunfeld; D Coyle; G A Perry
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

2.  [Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy].

Authors:  R Pötter; T H Knocke
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 3.621

3.  Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases.

Authors:  Jin Hwi Kim; Sung Jong Lee; Jeong Hoon Bae; Sung Ha Lee; Seog Nyeon Bae; Sung Eun Namkoong; Jong Sup Park
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.